Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SeerSEER +1.00%53 EV-to-OCF is 0.42 as of Aug. 22, 2026, which is 66% below its 10-year median of 1.24. GuruFocus rates SEER with a GF Score™ of 53/100 and a GF Value™ of $2.04 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,407 Biotechnology companies, Seer ranks worse than 75.69% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Seer's Enterprise Value is $-18.06 Mil.
Seer's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-43.38 Mil. Therefore, Seer's EV-to-OCF for today is 0.42.
The historical rank and industry rank for Seer's EV-to-OCF or its related term are showing as below:
SEER'
s EV-to-OCF Range Over the Past 10 Years
Min: -59.27 Med: 1.24 Max: 3.46
Current: 0.42
During the past 8 years, the highest EV-to-OCF of Seer was 3.46. The lowest was -59.27. And the median was 1.24.
SEER's EV-to-OCF is ranked worse than 75.69% of 1407
companies
in the Biotechnology industry
Industry Median: -3.61
vs SEER: 0.42
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-22), Seer's stock price is $2.03.
Seer's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.220. Therefore, Seer's PE Ratio (TTM) for today is At Loss.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Seer's share price for today is $2.03.
Seer's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Seer EV-to-OCF Related Terms
Seer EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Seer's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Seer's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seer EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seer's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Seer's EV-to-OCF falls into.
Seer's current Enterprise Value is $-18.06 Mil.
Seer's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seer (SEER) has a EV-to-OCF of 0.42 as of Aug. 22, 2026. This is 66% below median its historical median of 1.24. According to the industry distribution chart, Seer ranks #1065 out of 1407 companies in the Biotechnology industry, placing it in the top 75.7%.
Is Seer's EV-to-OCF too high?
Seer's current EV-to-OCF of 0.42 is 66% below median its 10-year median of 1.24. Based on the distribution chart, Seer ranks #1065 out of 1407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Seer has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Seer's EV-to-OCF compare to VANI and FBIO?
According to the Biotechnology industry distribution chart, Seer ranks #1065 out of 1407 companies for EV-to-OCF. This places Seer in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Seer's current EV-to-OCF is 0.42, which is 66% below median its own 10-year median of 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seer stock overvalued right now?
Based on GuruFocus' analysis, Seer (SEER) is currently considered Fairly Valued. The stock's GF Value™ is $2.04, compared to a current price of $2.03 — trading 0.5% below its estimated fair value. The current EV-to-OCF is 0.42, which is 66% below median its 10-year median of 1.24. Seer's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Seer (SEER), the current EV-to-OCF is 0.42 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seer (SEER) Overvalued in 2026?
Based on GuruFocus' analysis, Seer stock appears to be undervalued.
The current stock price of $2.03 is trading 0.5% below its estimated GF Value™ of $2.04.
GuruFocus considers Seer to be Fairly Valued.
Key valuation signals for SEER:
EV-to-OCF: 0.42 (66% below median its 10-year median of 1.24)
GF Value™: $2.04 vs. price of $2.03 (0.5% below fair value)
No single metric tells the full story. See the SEER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
53GF Score
Get the complete analysis for SEER
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEER has been successfully added to your 
